If this file opens in Compatibility Mode using Microsoft Word, convert to the latest document format to avoid potential formatting issues.	

OP RESEARCH PRO00036985 NCT05132504 PRE-OP, SURGERY, POST-OP ESNAOLA	

Types:      Research Oncology Treatment
Synonyms:  H50168 , PEMBRO

Pre-OP  (-42 Days)	Repeat 1 time	Cycle length: 42 days	Day -42	Perform every 1 day x1			Research tolerance: -0/+0 days	Provider Communication
  	ONC PROVIDER COMMUNICATION	Interval: --	Occurrences: --	Comments:	Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    MISP Pembrolizum FOLFIRINOX NA PDAC trial 10.12.22.pdf
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: --	Occurrences: --	Comments:	History/ Physical exam.
		  	ONC NURSING COMMUNICATION 5	Interval: --	Occurrences: --	Comments:	ECOG PS
		  	ONC NURSING COMMUNICATION 8	Interval: --	Occurrences: --	Comments:	AE assessment
		  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Toxicity assessment
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	Staging Eval
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --			Labs
  	CANCER ANTIGEN 19-9	Interval: --	Occurrences: --			Labs
  	THYROID STIMULATING HORMONE	Interval: --	Occurrences: --		  	T3, FREE	Interval: --	Occurrences: --		  	T4, FREE	Interval: --	Occurrences: --			Imaging
☑	CT CHEST W WO CONTRAST ABDOMEN W WO CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI ABDOMEN WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Serum
					
Surgery	Repeat 1 time	Cycle length: 1 day	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Provider Communication
  	ONC PROVIDER COMMUNICATION	Interval: --	Occurrences: --	Comments:	Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    MISP Pembrolizum FOLFIRINOX NA PDAC trial 10.12.22.pdf
			Nursing Orders
  	ONC NURSING COMMUNICATION 8	Interval: --	Occurrences: --	Comments:	AE assessment
		  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Toxicity assessment
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Surgical Resection
					
Post-OP (42 Days)	Repeat 1 time	Cycle length: 42 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Provider Communication
  	ONC PROVIDER COMMUNICATION	Interval: --	Occurrences: --	Comments:	Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    MISP Pembrolizum FOLFIRINOX NA PDAC trial 10.12.22.pdf
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: --	Occurrences: --	Comments:	History/ Physical exam.
		  	ONC NURSING COMMUNICATION 5	Interval: --	Occurrences: --	Comments:	ECOG PS
		  	ONC NURSING COMMUNICATION 8	Interval: --	Occurrences: --	Comments:	AE assessment
		  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Toxicity assessment
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	Staging Eval
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Pathologist Processing
		  	ONC NURSING COMMUNICATION 12	Interval: --	Occurrences: --	Comments:	Resection Margin
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Response Assessment
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --			Labs
  	CANCER ANTIGEN 19-9	Interval: --	Occurrences: --			Imaging
☑	CT CHEST W WO CONTRAST ABDOMEN W WO CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI CHEST WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI ABDOMEN WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
		☐	MRI PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	CT or MRI
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Serum